

14th December 2023

- | | |
|---|---|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Acquisition of additional stake in GoApptiv Private Limited

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and further to our intimation dated 10th June 2020 and 27th June 2022, we hereby notify that Cipla has entered into definitive agreements on 14th December 2023 for further investment of INR 42 crores (approx.) in GoApptiv Private Limited.

Details required to be disclosed under the SEBI Listing Regulations, 2015 read with circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 have been provided in Annexure – I to this letter.

We request you to kindly take the above disclosure on record.

Thanking you,
Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Muskan Jain

Annexure – I

Details as per the SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	<p>Name of the target entity: GoApptiv Private Limited (hereinafter referred to as “GoApptiv”)</p> <p>Brief details: GoApptiv, incorporated under the provisions of Companies Act, 2013, is a digital tech-company that offers end to end business solutions including distribution, digital solutions, integrated brand sales management, digital marketing, patient support and healthcare data analytics, channel engagement etc., for healthcare companies, to commercialise and improve access of healthcare product reach in tier 2-6 geographies through engagement with all stakeholders in the value chain leveraging proprietary technology platforms and physical reach. GoApptiv has developed digital applications for doctors, distributors, chemists and data analytics for efficient brand marketing for healthcare companies.</p> <p>Turnover: INR 864.64 crores for the year ended 31st March 2023.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>GoApptiv is an associate of the Company and hence the said acquisition would fall within the purview of related party transactions.</p> <p>The acquisition and subscription of shares will be at “arm’s length” basis valuation report received from independent valuers as per applicable laws.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs;	Digi-tech and Healthcare Industry.

d)	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The follow-on investment shall strengthen Cipla's partnership with GoApptiv, enabling penetration into under-served rural areas of India and address critical healthcare gaps where pharmaceutical coverage is limited. This expanded investment will enhance our collective abilities to deliver patient-centric solutions and will add to our digitisation agenda.
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable.
f)	Indicative time-period for completion of the acquisition;	The transaction is expected to be completed within 60 days of signing of definitive agreements or such other date mutually agreed between the parties and shall be subject to successful completion/waiver of conditions precedent as mentioned in such definitive agreements.
g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration.
h)	Cost of acquisition and/or the price at which the shares are acquired	INR 42 crore (approx.) in following manner: 1. Acquisition of 1,904 Equity Shares of face value INR 10 per share; 2. Subscription to 9,526 Series B Compulsorily Convertible Preference Shares of face value INR 10 per share. Cipla's stake in GoApptiv post completion of acquisition and subscription of additional shares would be 22.99%, on a fully diluted basis.
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: Refer (a) above. Date of Incorporation: 27 th March 2015 History of last 3 years turnover: FY 22-23: INR 864.64 crores FY 21-22: INR 131.85 crores FY 20-21: INR 59.81 crores Country in which GoApptiv has its presence: India

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

 P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380